Study 1. A randomized clinical trial recruited 144 antipsychotic-naive youths, mean age 11.3 years, who were diagnosed with 1 or more psychiatric disorders and clinically significant aggression. The patients were randomized to 1 of 3 antipsychotics (oral aripiprazole, olanzapine or risperidone) commonly used in children with disruptive behavioral disorders and then evaluated for 12 weeks.
From baseline to week 12, insulin-stimulated change in glucose rate of disappearance increased by 2.3% for risperidone and decreased by 29.34% for olanzapine and 30.26% for aripiprazole, with no significant difference across medications. This primary measure of insulin sensitivity decreased significantly during 12 weeks in the pooled study sample.
Percentage total body fat increased by 1.18% on risperidone, 4.12% on olanzapine, and 1.66% on aripiprazole and was significantly greater for olanzapine than risperidone or aripiprazole.